{"id":3334,"count":25,"description":"Kategorie hepatitidov\u00fdch l\u00e9k\u016f na MedsBase zahrnuje peror\u00e1ln\u00ed antivirotika pro dva odli\u0161n\u00e9 typy chronick\u00fdch virov\u00fdch infekc\u00ed jater, kter\u00e9 lze skute\u010dn\u011b l\u00e9\u010dit tabletami \u2014 chronick\u00e1 hepatitida B (HBV)<\/strong> a chronick\u00e1 hepatitida C (HCV)<\/strong> — along with the tenofovir-based combinations used for both HBV suppression and HIV pre-exposure prophylaxis. Each treatment class has its own goal, mechanism and duration. Choosing the right medication starts with knowing which virus you are treating, your kidney function, and whether you are co-infected with HIV.\n\nHepatitis C: 12-week direct-acting antiviral (DAA) cure\nHCV is the only chronic viral hepatitis that current oral therapy can vyl\u00e9\u010dit<\/em>. P\u0159\u00edm\u00e1 antivirotika (DAA) sou\u010dasn\u011b c\u00edl\u00ed na HCV NS5B polymer\u00e1zu a NS5A replika\u010dn\u00ed komplex. V\u00fdsledkem je trval\u00e1 virologick\u00e1 odpov\u011b\u010f (SVR12) \u2014 HCV RNA nedetekovateln\u00e1 12 t\u00fddn\u016f po posledn\u00ed tablet\u011b \u2014 u 95 % nebo v\u00edce pacient\u016f bez cirh\u00f3zy, kte\u0159\u00ed dosud nebyli l\u00e9\u010deni. L\u00e9\u010dba trv\u00e1 12 t\u00fddn\u016f; po vyl\u00e9\u010den\u00ed nen\u00ed nutn\u00e1 dal\u0161\u00ed antivirov\u00e1 terapie.\n\nHepcinat LP<\/strong><\/a> — sofosbuvir 400 mg + ledipasvir 90 mg, generic Harvoni. First-line for HCV genotypes 1, 4, 5 and 6.\n\n\nHepatitis B: long-term suppression with tenofovir\nUnlike HCV, chronic hepatitis B is currently a manageable infection rather than a curable one. The cccDNA template inside infected hepatocytes is not eliminated by any oral drug, which is why HBV treatment is usually long-term. The goal is undetectable HBV DNA, normal ALT, and prevention of cirrhosis and hepatocellular carcinoma. Two tenofovir formulations dominate guidelines (EASL, AASLD, APASL, WHO):\n\nTenvir<\/strong><\/a> \u2014 tenofovir disoproxil fumar\u00e1t (TDF) 300 mg od Cipla. Bezpe\u010dnostn\u00ed data za 20+ let; preferov\u00e1no v t\u011bhotenstv\u00ed.\nTeravir<\/strong><\/a> \u2014 tenofovir disoproxil fumar\u00e1t 300 mg od Cipla, alternativn\u00ed zna\u010dka TDF.\nTenvir AF<\/strong><\/a> — tenofovir alafenamide (TAF) 25 mg by Cipla, generic Vemlidy. Same active metabolite as TDF, but ~90% lower plasma exposure: substantially less renal and bone toxicity. Preferred in chronic kidney disease, osteoporosis, age > 60, or pre-existing TDF toxicity.\n\n\nHIV pre-exposure prophylaxis (PrEP) and treatment-combination tablets\nThe same tenofovir backbone, when combined with emtricitabine (FTC), is the standard for HIV pre-exposure prophylaxis — reducing HIV acquisition risk by > 99% when taken daily as directed. These products are listed in this category because TDF alone is also active against HBV; in HBV\/HIV co-infection a single combination tablet covers both. Three branded generics of Truvada are stocked here:\n\nTenvir-EM<\/strong><\/a> \u2014 TDF 300 + FTC 200 od Cipla.\nRicovir EM<\/strong><\/a> \u2014 TDF 300 + FTC 200 od Mylan.\nTenof EM<\/strong><\/a> — TDF 300 + FTC 200 by Hetero.\n\nDaily PrEP, the 2-1-1 event-based regimen (cisgender MSM only), or HIV combination treatment all start with the same molecule. Choice between the three brands is largely about manufacturer preference and stock; pharmacology is identical.\n\nChoosing between options\n\n\n\nNeed\nRecommended starting point\n\n\n\nHepatitis C cure (genotype 1\/4\/5\/6)Hepcinat LP, 12-week course.\nChronic HBV, normal kidneys, age < 60Tenvir or Teravir (TDF 300).\nChronic HBV with CKD, osteoporosis, or age > 60Tenvir AF (TAF 25).\nHIV PrEP — daily or 2-1-1Tenvir-EM, Ricovir EM or Tenof EM (TDF\/FTC).\nHBV + HIV co-infectionA TDF\/FTC combination — covers both.\n\n\n\nAll hepatitis B and HIV regimens require baseline workup (HBV DNA or HIV RNA, HBeAg\/HBsAg, eGFR, ALT, hepatitis screening, lipid panel) and ongoing specialist monitoring. Hepatitis C treatment also benefits from hepatologist supervision, especially if there is any cirrhosis or co-medication that interacts with DAAs. MedsBase supplies the medication; clinical monitoring should be set up locally.","link":"https:\/\/medsbase.com\/cs\/hepatitis-medication\/","name":"L\u00e9ky na hepatitidu","slug":"hepatitis-medication","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product?product_cat=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}